Maytansinoid DM4

Cat. No.: HY-100503: Ficha de datos Instrucciones de manejo
FAQs
Technical Support

Maytansinoid DM4 is a thiol-containing maytansine derivative with highly potent cytotoxicity. Maytansinoid DM4 can be used as a cytotoxic moiety of ADC.

Para uso exclusivo en investigación. No vendemos a pacientes.

Maytansinoid DM4 Estructura química

No. CAS : 799840-96-3

Tamaño		Stock
MOQ		Minimum order quantity
50 mg		Obtener un presupuesto
100 mg		Obtener un presupuesto
250 mg		Obtener un presupuesto
Other size		Obtener un presupuesto

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Other Forms of Maytansinoid DM4:

DM4 In-stock

Recomendaciones destacadas

•Related Small Molecules:

•Related Proteins:

Ver todos los productos específicos de isoformas ADC Payload:

Ver todas las isoformas

Auristatin Calicheamicins Camptothecins Daunorubicins/Doxorubicins Duocarmycins Maytansinoids Pyrrolobenzodiazepines Traditional Cytotoxic Agents

Actividad biológica
Pureza y Documentación
Referencias
Revisión del cliente

Descripciòn

Maytansinoid DM4 is a thiol-containing maytansine derivative with highly potent cytotoxicity. Maytansinoid DM4 can be used as a cytotoxic moiety of ADC^[1]^[2].

IC₅₀ & Target^[1]^[2]

Maytansinoids

In Vitro

Maytansine is a natural benzoansamacrolide product isolated from the bark of the African shrub Maytenus ovatus. Maytansine binds to the same site on tubulin as the vinca alkaloids, with similar in vitro inhibition constants, but is a more-potent cytotoxin^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Peso molecular

794.39

Fòrmula

C₃₉H₅₆ClN₃O₁₀S

No. CAS

799840-96-3

SMILES

C[C@]1([C@H](CC(N(C(C=C(C2)C=C3OC)=C3Cl)C)=O)OC([C@H](C)N(C)C(CCC(C)(S)C)=O)=O)[C@@](C(C)([C@](OC4=O)([H])C[C@]([C@@H](/C=C/C=C2\C)OC)(N4)O)C)([H])O1

Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Please store the product under the recommended conditions in the Certificate of Analysis.

Pureza y Documentación

Instrucciones de manejo (2659 KB)

Referencias

[1]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337. [Content Brief]

[2]. Zhao RY, et al. Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates. J Med Chem. 2011 May 26;54(10):3606-23. [Content Brief]